BD Gets 510K Clearance for Nasopharyngeal Wash
BD Diagnostics, a segment of BD (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD Veritor™ System for Rapid Detection of Flu A+B. This new product is cleared for use in clinical settings.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.